Gold prices head for first weekly drop in 10 weeks; US CPI data awaited
Investing.com -- Scienture Holdings Inc (NASDAQ:SCNX) stock surged 61.4% after the company announced it has begun commercial sales and fulfillment of the first customer orders for Arbli™, its FDA-approved oral suspension formulation of losartan potassium.
Arbli™ is the first ready-to-use oral suspension of losartan potassium to receive FDA approval, providing an alternative for patients who cannot take solid dosage forms. The product enters a substantial market, with U.S. losartan sales totaling approximately $256 million annually and over 71 million prescriptions written each year, according to IQVIA data.
The company has implemented a targeted outreach campaign to healthcare professionals and has secured PBM-Led GPO agreements to expand commercial coverage and formulary access. Scienture has also established multiple commercial group purchasing organization agreements, extending Arbli’s market access to over 2,500 healthcare institutions nationwide, representing an estimated 20% of the U.S. institutional market.
"The start of commercial sales for Arbli™ represents a major achievement for Scienture as we transition from development to execution," said Narasimhan Mani, President and co-CEO of Scienture. "As promotional efforts expand and demand builds across retail, institutional and long-term care markets, we see significant potential for sustained adoption and value creation."
The company’s institutional agreements cover hospitals, clinics, nursing homes, specialty pharmacies, long-term care facilities, and ambulatory centers, establishing a broad footprint that strengthens Scienture’s commercial reach as it begins marketing this differentiated product.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.